A 17-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Of Pregabalin For The Treatment Of Chronic Central Neuropathic Pain After Spinal Cord Injury.

Trial Profile

A 17-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Of Pregabalin For The Treatment Of Chronic Central Neuropathic Pain After Spinal Cord Injury.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Neuropathic pain
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Nov 2016 Results of a retrospective analysis from NCT00394901, NCT00553475, NCT00407745, NCT00424372, NCT00553280, NCT01202227 studies, published in the Clinical Drug Investigation
    • 20 May 2016 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information; JapicCTI101335)
    • 03 May 2014 Results from a pooled analysis presented at the 33rd Annual Scientific Meeting of the American Pain Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top